RWS registered its best ever revenue and profits figures in FY 2017 and declared its 14th consecutive dividend increase. Recent acquisitions in Life Sciences contribute significantly to the bottom line. Continue reading
life sciences translation
RWS reports 33.6% revenue growth and projects pre-tax profits “ahead of market expectations” for its financial year ending September 30, 2017. Market capitalization nears USD 1.3bn on the back of surge in share price. Continue reading
RWS delivers yet another set of strong results as share price hovers near all-time high. Revenues are up 35% and operating profits up 28% in the first six months of the financial year. Chairman Andrew Brode says they occasionally compete with TransPerfect but would never consider buying them. Continue reading
Advertisement
As global corporations optimize procurement across their global operations, they look to consolidate translation spend in a single framework. At SlatorCon London, Steve Kirk, Chief Procurement Officer at QuintilesIMS, discussed how the world’s largest clinical research organization manages language services. Continue reading
The EU is expected to enact a sweeping overhaul of its regulatory framework for medical devices in early 2017, which includes changes to requirements for multilingual documentation. Brexit also adds to uncertainty. Continue reading
RWS adds another USD 80m to its market capitalization as shares rise more than 12% after the company publishes a record set of numbers. Its strong financial position makes RWS a key player for acquisitions. Continue reading
This information will never be shared with third parties. No Spam.